What is a latex allergy like
Peak levels of immunoglobulin G are obtained approximately 2 days after intramuscular injection of GamaSTAN S/D.(1) The half-life of IgG in the circulation of individuals with normal IgG levels is 23 days.(2)
Passive immunization with GamaSTAN S/D modifies hepatitis A, prevents or modifies measles, and provides replacement therapy in persons with hypogammaglobulinemia or agammaglobulinemia. GamaSTAN S/D is not standardized with honor to antibody titers against hepatitis B surface antigen (HBsAg) and should not be used for prophylaxis of viral hepatitis type B.
Prophylactic treatment to prevent hepatitis B can best be accomplished with use of Hepatitis B Immune Globulin (Human), often in combination with Hepatitis B Vaccine.(3)
GamaSTAN S/D may be of benefit in women who own been exposed to rubella in the first trimester of pregnancy and who will not consider a therapeutic abortion.(4) GamaSTAN S/D may also be considered for use in immunocompromised patients for passive immunization against varicella if Varicella-Zoster Immune Globulin (Human) is not available.(5)
Immune Globulin (Human) is not indicated for routine prophylaxis or treatment of rubella, poliomyelitis, mumps, or varicella.
It is not indicated for allergy or asthma in patients who own normal levels of immunoglobulin.(6)
In a clinical study in eight healthy human adults receiving another hyperimmune immune globulin product treated with solvent/detergent, Rabies Immune Globulin (Human), HyperRAB™ S/D, prepared by the same manufacturing process, detectable passive antibody titers were observed in the serum of every subjects by 24 hours post injection and persisted through the 21 day study period.
These results propose that passive immunization with immune globulin products is not affected by the solvent/detergent treatment.
Indications and Usage for GamaSTAN S/D
Passive immunization against varicella in immunosuppressed patients is best accomplished by use of Varicella-Zoster Immune Globulin (Human) [VZIG]. If VZIG is unavailable, GamaSTAN S/D, promptly given, may also modify varicella.(5)
The routine use of GamaSTAN S/D for prophylaxis of rubella in early pregnancy is of dubious worth and cannot be justified.(6) Some studies propose that the use of GamaSTAN S/D in exposed, susceptible women can lessen the likelihood of infection and fetal damage; therefore, GamaSTAN S/D may benefit those women who will not consider a therapeutic abortion.(4)
The prophylactic worth of GamaSTAN S/D is greatest when given before or soon after exposure to hepatitis A.
GamaSTAN S/D is not indicated in persons with clinical manifestations of hepatitis A or in those exposed more than 2 weeks previously.
GamaSTAN S/D should be given to prevent or modify measles in a susceptible person exposed fewer than 6 days previously.(7) A susceptible person is one who has not been vaccinated and has not had measles previously. GamaSTAN S/D may be especially indicated for susceptible household contacts of measles patients, particularly contacts under 1 year of age, for whom the risk of complications is highest.(7)GamaSTAN S/D and measles vaccine should not be given at the same time.(7) If a kid is older than 12 months and has received GamaSTAN S/D, he should be given measles vaccine about 3 months later when the measles antibody titer will own disappeared.
If a susceptible kid exposed to measles is immunocompromised, GamaSTAN S/D should be given immediately.(8)
Children who are immunocompromised should not get measles vaccine or any other live viral vaccine.
In patients with immunoglobulin deficiencies, GamaSTAN S/D may prevent serious infection.
However, GamaSTAN S/D may not prevent chronic infections of the external secretory tissues such as the respiratory and gastrointestinal tract.
Prophylactic therapy, especially against infections due to encapsulated bacteria, is effective in Bruton-type, sex-linked, congenital agammaglobulinemia, agammaglobulinemia associated with thymoma, and acquired agammaglobulinemia.
GamaSTAN S/D should not be given to persons with isolated immunoglobulin A (IgA) deficiency.
Such persons own the potential for developing antibodies to IgA and could own anaphylactic reactions to subsequent istration of blood products that contain IgA.(9)
GamaSTAN S/D should not be istered to patients who own severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.
|There was an error with your session.|
|If issues persist, please contact our customer service department|
|at 1-800-295-5510 or [email protected]|
|Error 1000 — ID: 18.f9be1402.1580312317.2fb46db6|
Generic Name: immune globulin (human)
Dosage Form: injection
Medically reviewed by Drugs.com.
Final updated on Sep 23, 2019.
Clinically Significant Product Interactions
Antibodies in the globulin preparation may interfere with the response to live viral vaccines such as measles, mumps, polio and rubella. Therefore, use of such vaccines should be deferred until approximately 3 months after Immune Globulin (Human) — GamaSTAN™ S/D istration.
No interactions with other products are known.
Pregnancy Category C
Animal reproduction studies own not been conducted with GamaSTAN S/D.
It is also not known whether GamaSTAN S/D can cause fetal harm when istered to a pregnant lady or can affect reproduction capacity. GamaSTAN S/D should be given to a pregnant lady only if clearly needed.
Immune Globulin (Human) should not be istered intravenously because of the potential for serious reactions. Injections should be made intramuscularly, and care should be taken to draw back on the plunger of the syringe before injection in order to be certain that the needle is not in a blood vessel.
Skin tests should not be done. In most human beings the intradermal injection of concentrated gamma globulin solution with its buffers causes a localized area of inflammation which can be misinterpreted as a positive allergic reaction.
In actuality, this does not represent an allergy; rather, it is localized tissue irritation of a chemical nature. Misinterpretation of the results of such tests can lead the physician to withhold badly needed human immunoglobulin from a patient who is not actually allergic to this material. True allergic responses to human gamma globulin given in the prescribed intramuscular manner are rare.
Although systemic reactions to intramuscularly istered immunoglobulin preparations are rare, epinephrine should be available for treatment of acute allergic symptoms.
Clinical and Laboratory Tests
Safety and effectiveness in the pediatric population own not been established.
GamaSTAN S/D is made from human plasma.
Products made from human plasma may contain infectious agents, such as viruses, and, theoretically, the Creutzfeldt-Jakob Disease (CJD) agent that can cause disease.
The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections, and by inactivating and/or removing certain viruses. Despite these measures, such products can still potentially transmit disease. There is also the possibility that unknown infectious agents may be present in such products.
Individuals who get infusions of blood or plasma products may develop signs and/or symptoms of some viral infections, particularly hepatitis C. Every infections thought by a physician possibly to own been transmitted by this product should be reported by the physician or other healthcare provider to Talecris Biotherapeutics, Inc.
The physician should discuss the risks and benefits of this product with the patient, before prescribing or istering it to the patient.
GamaSTAN S/D should be given with caution to patients with a history of prior systemic allergic reactions following the istration of human immunoglobulin preparations.(9)
GamaSTAN S/D Description
Immune Globulin (Human) — GamaSTAN™ S/D treated with solvent/detergent is a sterile solution of immune globulin for intramuscular istration; it is preservative-free and latex-free. GamaSTAN S/D is prepared by freezing ethanol fractionation from human plasma.
The immune globulin is isolated from solubilized Cohn part II.
The part II solution is adjusted to a final concentration of 0.3% tri-n-butyl phosphate (TNBP) and 0.2% sodium cholate. After the addition of solvent (TNBP) and detergent (sodium cholate), the solution is heated to 30°C and maintained at that temperature for not less than 6 hours. After the viral inactivation step, the reactants are removed by precipitation, filtration and finally ultrafiltration and diafiltration. GamaSTAN S/D is formulated as a 15–18% protein solution at a pH of 6.4–7.2 in 0.21–0.32 M glycine.
GamaSTAN S/D is then incubated in the final container for 21–28 days at 20–27°C.
The removal and inactivation of spiked model enveloped and non-enveloped viruses during the manufacturing process for GamaSTAN S/D has been validated in laboratory studies. Human Immunodeficiency Virus, Type 1 (HIV-1), was chosen as the relevant virus for blood products; Bovine Viral Diarrhea Virus (BVDV) was chosen to model Hepatitis C virus; Pseudorabies virus (PRV) was chosen to model Human Herpes viruses and other large enveloped DNA viruses; and Reo virus type 3 (Reo) was chosen to model non-enveloped viruses and for its resistance to physical and chemical inactivation.
Significant removal of model enveloped and non-enveloped viruses is achieved at two steps in the Cohn fractionation process leading to the collection of Cohn Part II: the precipitation and removal of Part III in the processing of Part II + IIIW suspension to Effluent III and the filtration step in the processing of Effluent III to Filtrate III. Significant inactivation of enveloped viruses is achieved at the time of treatment of solubilized Cohn Part II with TNBP/sodium cholate.
Additionally, the manufacturing process was investigated for its capacity to decrease the infectivity of an experimental agent of transmissible spongiform encephalopathy (TSE), considered as a model for the vCJD and CJD agents.(11-14)
Studies of the GamaSTAN S/D manufacturing process protest that TSE clearance is achieved during the Pooled Plasma to Effluent III Fractionation Process (6.7 log10).
These studies provide reasonable assurance that low levels of CJD/vCJD agent infectivity, if present in the starting material, would be removed.